BioSpace News Archive

Neovasc, Inc. (“Neovasc” or the “Company”) ( NASDAQ , TSX : NVCN), announced today that it has been informed by the U.S. Food and Drug Administration (FDA) that the Circulatory System Devices Panel of the Medical Devices Advisory Committee will review the premarket approval application (PMA) for the Neovasc Reducer™ device (“Reducer”) at its October 27, 2020 meeting. Neovasc is seeking approval for Reducer in t

MediPharm Labs Corp ., (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) (“MediPharm Labs” or the “Company”) a global leader in specialized, research-driven pharmaceutical-quality cannabis extraction, distillation and derivative products, is pleased to announce that MediPharm Labs’ management will participate in the CBD BioPharma Virtual Investor Conference on Thursday, July 9 th . The audio webcast presentation will begin at 11:30am Eastern Time. Pa

Tris Pharma, Inc. (“Tris”), a specialty pharmaceutical company with a robust portfolio of FDA-approved products for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) and related disorders, and KYE Pharmaceuticals Inc. (“KYE”), a private company headquartered in Mississauga, Ontario a

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that on July 28, 2020, at 12:00 p.m. EDT it will host a key opinion leader webinar on ARO-ENaC, the company’s investigational RNA interference (RNAi) therapeutic being developed as a treatment for patients with cystic fibrosis (CF). The webinar will feature a presentation by Marcus Mall, M.D., Professor and Director of the Department of Pediatric P

NuMedii, Inc., a data-driven drug discovery company, today announced the availability of the world’s first single-cell sequencing atlas for idiopathic pulmonary fibrosis (IPF) that was the result of a strategic research collaboration including the Yale School of Medicine, Baylor College of Medicine, Brigham and Women’s Hospital, and NuMedii.

OliX Pharmaceuticals, Inc . (KOSDAQ: 226950), a leading developer of RNAi therapeutics, today announced that Dong Ki Lee, Ph.D., founder and Chief Executive Officer of the Company will present its platform technology and discuss the potential utility of Asymmetric small interfering RNA (asiRNA), Cell-Penetrating Asymmetric Interfering RNA (cp-asiRNA) and GalNAc-asiRNA at the global Virtual RNAi-Based Therapeutics Summit on Wed

Published work highlights the preclinical development of BND-22, an anti-ILT2 multi-cell checkpoint inhibitor that enhances the anti-tumor activity of innate and adaptive immune cells Also, first publication of a regulatory mechanism of the CD28/B7 immune stimulatory pathway, identifying CD28 shedding as a potential novel target for cancer therapeutics MISGAV, Israel, July 09, 2020 (GLOBE NEWSWIRE) -- Biond Biologics Ltd. (“Biond” or the “Company”), a privately-held biopharmaceuti

Soliton, Inc. (Nasdaq: SOLY) (“Soliton” or the “Company”), a medical device company with a novel and proprietary aesthetic platform technology, today announced that Company CEO Chris Capelli has been invited to present at the Re-Engaging Medical Practices in an Era of COVID-19 webinar, presented by Maxim Group and M-Vest on Thursday July 16th, 2020

BioReference Laboratories, Inc., an OPKO Health company (NASDAQ: OPK), will conduct COVID-19 testing for all Major League Soccer (MLS) players as well as match officials, and Club and League staff participating in the MLS is Back Tournament.

Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSXV:TBP)(OTCQB:TBPMF), a leader in cannabinoid-derived drug discovery and development, is pleased to announce that it has appointed Steve Edgett as a Strategic Advisor. Mr. Edgett will act as a special advisor to the CEO and the Board of Directors with a mandate to advise on strategic and capital markets aspects of the Company’s activities and to aid in the advancement of our key programs: ARDS-003, QIXLEEF™ and CAUMZ™.